GLAXO WELLCOME BPH COMPOUND TO BEGIN PHASE II, QOL TRIALS EARLY 1996; IRRITABLE BOWEL SYNDROME COMPOUNDS IN ONGOING PHASE II CLINICAL TRIALS
Executive Summary
Glaxo Wellcome compound GI198745 for benign prostatic hyperplasia is scheduled to enter Phase II trials in early 1996, Glaxo Wellcome R&D Medical Group Operations Director James Palmer announced Nov. 10 at the company's R&D analyst meeting in New York City.